Gender Dysphoria Pipeline Analysis Report, 2024: Emerging Therapies, Drugs, Leading Companies, Unmet Needs And More

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Gender Dysphoria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets's offering.
This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Gender dysphoria market. A detailed picture of the Gender dysphoria pipeline landscape is provided, which includes the disease overview and Gender dysphoria treatment guidelines.

The assessment part of the report embraces in-depth Gender dysphoria commercial assessment and clinical assessment of the Gender dysphoria pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gender dysphoria collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:

• All of the companies that are developing therapies for the treatment of Gender dysphoria with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Gender dysphoria treatment.
• Gender dysphoria key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Gender dysphoria market.

Key Questions Answered

• What are the current options for Gender dysphoria treatment?
• How many companies are developing therapies for the treatment of Gender dysphoria?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for the treatment of Gender dysphoria?
• How many Gender dysphoria emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Gender dysphoria?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Gender dysphoria market?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Gender dysphoria?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Gender dysphoria therapies?
• What are the clinical studies going on for Gender dysphoria and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for Gender dysphoria?
• How many patents are granted and pending for the emerging therapies for the treatment of Gender dysphoria?

Key Topics Covered
1. Report Introduction
2. Gender Dysphoria
3. Gender Dysphoria Current Treatment Patterns
4. Gender Dysphoria - Analytical Perspective
5. Therapeutic Assessment
6. Gender Dysphoria Late Stage Products (Phase-III)
7. Gender Dysphoria Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gender Dysphoria Discontinued Products
13. Gender Dysphoria Product Profiles
14. Gender Dysphoria Key Companies
15. Gender Dysphoria Key Products
16. Dormant and Discontinued Products
17. Gender Dysphoria Unmet Needs
18. Gender Dysphoria Future Perspectives
19. Gender Dysphoria Analyst Review
20. Appendix
21. Report Methodology
For more information about this drug pipelines report visit

About ResearchAndMarkets
ResearchAndMarkets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN31052024004107003653ID1108280529